'Duplicate therapy' denials
The plan flagged your medication as duplicating another drug you're already taking. Appealable when the combination is clinically intended.
What this denial means
A duplicate-therapy denial means the plan's pharmacy benefit system flagged the new prescription as duplicating a drug class the patient is already on. The system catches obvious duplications (two long-acting opioids; two ACEIs) but often misfires on legitimate combination therapy (dual antiplatelet after stent; ICS + LABA inhaler; two ADHD stimulants for different times of day).
How to appeal it
Duplicate-therapy appeals win when the prescriber documents: (1) the clinical rationale for the combination (e.g., 'dual therapy is standard of care per ACC/AHA guideline for 12 months post-stent'); (2) the specific specialty-society guideline supporting the combination; (3) why the alternatives are inappropriate; (4) for ADHD or behavioral health combinations, the precise dosing schedule showing they're not actually competing at the same receptor target.
Frequently asked questions
What does “denied as duplicate therapy” mean?
A duplicate-therapy denial means the plan's pharmacy benefit system flagged the new prescription as duplicating a drug class the patient is already on. The system catches obvious duplications (two long-acting opioids; two ACEIs) but often misfires on legitimate combination therapy (dual antiplatelet after stent; ICS + LABA inhaler; two ADHD stimulants for different times of day).
How do I appeal a 'duplicate therapy' denials?
Duplicate-therapy appeals win when the prescriber documents: (1) the clinical rationale for the combination (e.g., 'dual therapy is standard of care per ACC/AHA guideline for 12 months post-stent'); (2) the specific specialty-society guideline supporting the combination; (3) why the alternatives are inappropriate; (4) for ADHD or behavioral health combinations, the precise dosing schedule showing they're not actually competing at the same receptor target.
Related
- CARC 18 — Exact duplicate claim/service.The carrier sees this as a duplicate of a claim already processed. Check whether the original was pa
- CARC 236 — This procedure or procedure/modifier combination is not comp…This procedure or procedure/modifier combination is not compatible with another procedure or procedu
- ERISA §503ERISA §503 is the foundational federal appeal-rights statute for the ~135 million Americans on emplo
- ACA §2719 (PHSA §2719)ACA §2719 guarantees every non-grandfathered group + individual health plan a standardised internal
- Mental health & behavioral healthInpatient psych, residential, PHP/IOP, therapy, TMS, Spravato
- Cardiology drugsPCSK9, Entresto, SGLT2, Vyndamax, Camzyos, Kerendia, Vascepa
- Asthma & severe allergiesXolair, Dupixent, Nucala, Tezspire, Neffy, Palforzia, EpiPen, allergy immunotherapy
- 'Experimental / investigational' denialsThe plan called the treatment experimental. Often misapplied — and reversible by citing FDA approval
- 'Not FDA-approved' denialsThe plan says the drug or its specific use isn't FDA-approved. Distinct from 'experimental' — and ap
- 'Not medically necessary' denialsThe single most common appealable denial. The insurer says the treatment isn't medically necessary b
- 'Prior authorization required' denialsThe service required pre-approval that wasn't obtained. Appealable when the auth was attempted, when
Appeal a 'duplicate therapy' denials denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com